Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm , Ulm, Germany .
Diabetes Technol Ther. 2017 Oct;19(10):580-588. doi: 10.1089/dia.2016.0408. Epub 2017 Jul 13.
Self-monitoring of blood glucose (BG) is an essential part of diabetes therapy. Accurate and reliable results from BG monitoring systems (BGMS) are important especially when they are used to calculate insulin doses. This study aimed at assessing system accuracy of BGMS and possibly related insulin dosing errors.
System accuracy of six different BGMS (Accu-Chek Aviva Nano, Accu-Chek Mobile, Accu-Chek Performa Nano, CONTOUR NEXT LINK 2.4, FreeStyle Lite, OneTouch Verio IQ) was assessed in comparison to a glucose oxidase and a hexokinase method. Study procedures and analysis were based on ISO 15197:2013/EN ISO 15197:2015, clause 6.3. In addition, insulin dosing error was modeled.
In the comparison against the glucose oxidase method, five out of six BGMS fulfilled ISO 15197:2013 accuracy criteria. Up to 14.3%/4.3%/0.3% of modeled doses resulted in errors exceeding ±0.5/±1.0/±1.5 U and missing the modeled target by 20 mg/dL/40 mg/dL/60 mg/dL, respectively. Compared against the hexokinase method, five out of six BGMS fulfilled ISO 15197:2013 accuracy criteria. Up to 25.0%/10.5%/3.2% of modeled doses resulted in errors exceeding ±0.5/±1.0/±1.5 U, respectively.
Differences in system accuracy were found, even among BGMS that fulfilled the minimum system accuracy criteria of ISO 15197:2013. In the error model, considerable insulin dosing errors resulted for some of the investigated systems. Diabetes patients on insulin therapy should be able to rely on their BGMS' readings; therefore, they require highly accurate BGMS, in particular, when making therapeutic decisions.
自我血糖监测(BG)是糖尿病治疗的重要组成部分。BG 监测系统(BGMS)的准确可靠结果非常重要,尤其是当它们用于计算胰岛素剂量时。本研究旨在评估 BGMS 的系统准确性,以及可能存在的相关胰岛素剂量错误。
本研究将六种不同的 BGMS(Accu-Chek Aviva Nano、Accu-Chek Mobile、Accu-Chek Performa Nano、CONTOUR NEXT LINK 2.4、FreeStyle Lite、OneTouch Verio IQ)与葡萄糖氧化酶法和己糖激酶法进行比较,以评估系统准确性。研究程序和分析基于 ISO 15197:2013/EN ISO 15197:2015 标准第 6.3 条。此外,还对胰岛素剂量错误进行了建模。
与葡萄糖氧化酶法相比,六种 BGMS 中有五种符合 ISO 15197:2013 的准确性标准。高达 14.3%/4.3%/0.3%的模型剂量会导致误差超过±0.5/±1.0/±1.5U,并且分别错过模型目标 20mg/dL/40mg/dL/60mg/dL。与己糖激酶法相比,六种 BGMS 中有五种符合 ISO 15197:2013 的准确性标准。高达 25.0%/10.5%/3.2%的模型剂量会导致误差超过±0.5/±1.0/±1.5U。
即使在符合 ISO 15197:2013 最低系统准确性标准的 BGMS 中,也发现了系统准确性的差异。在误差模型中,一些被调查的系统会导致相当大的胰岛素剂量错误。接受胰岛素治疗的糖尿病患者应该能够依赖他们的 BGMS 读数;因此,他们需要高度准确的 BGMS,尤其是在做出治疗决策时。